T cell receptor specific for influenza peptides (TCR (Influenza-specific))

The T cell receptor (TCR) specific for influenza peptides on CD4+ helper T cells is a critical component of the adaptive immune system's defense against the influenza virus. These receptors are heterodimeric proteins, typically composed of alpha and beta chains, that recognize viral epitopes presented by Major Histocompatibility Complex Class II (MHC II) molecules on the surface of professional antigen-presenting cells (APCs) [1][2]. Upon recognition of specific influenza peptides, such as those derived from hemagglutinin, nucleoprotein, or matrix proteins, the TCR initiates a signaling cascade that activates the CD4+ T cell [3]. This activation leads to the production of cytokines like IL-2 and IFN-gamma, which are essential for providing help to B cells for antibody production and to CD8+ T cells for cytotoxic activity [4]. In a therapeutic context, these TCRs are the primary targets for universal influenza vaccines designed to elicit broad, cross-reactive T-cell responses across different viral strains [5]. Furthermore, engineered TCR-T cell therapies are being investigated to treat severe or refractory influenza infections by providing patients with pre-activated, virus-specific T cells [6]. The diversity of the TCR repertoire determines the breadth of the immune response, making it a key focus for monitoring vaccine efficacy and disease progression [7]. Challenges in targeting these receptors include the high variability of influenza strains and the requirement for specific HLA matching in TCR-based therapies [8]. Overall, the influenza-specific TCR on CD4+ cells represents a pivotal node for both natural immunity and advanced immunotherapeutic strategies against seasonal and pandemic flu [9]. Sources: [1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655099/ [2] https://pubmed.ncbi.nlm.nih.gov/22407916/ [3] https://www.nature.com/articles/s41577-019-0143-6 [4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547657/ [5] https://clinicaltrials.gov/ (Search for M-001 or universal flu vaccines) [6] https://www.frontiersin.org/articles/10.3389/fimmu.2020.01762/full [7] https://www.jimmunol.org/content/188/7/3404 [8] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463100/ [9] https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/influenza

Other names

Influenza-specific T-cell receptorCD4+ T-cell receptorAntigen-specific TCRTCR-CD3 complex

The TCR recognizes specific influenza-derived peptides presented by Major Histocompatibility Complex (MHC) Class II molecules on antigen-presenting cells. This binding triggers a signaling cascade through the CD3 complex and ZAP-70, leading to the activation of transcription factors like NFAT and NF-kB, which drive CD4+ T cell differentiation and the secretion of cytokines to coordinate the adaptive immune response.